Fusion Antibodies (LON:FAB) Shares Up 17.2% – Should You Buy?

Fusion Antibodies plc (LON:FAB)’s share price rose 17.2% on Tuesday . The stock traded as high as GBX 8.50 ($0.11) and last traded at GBX 8.50 ($0.11). Approximately 1,030,108 shares were traded during mid-day trading, a decline of 39% from the average daily volume of 1,693,661 shares. The stock had previously closed at GBX 7.25 ($0.09).

Fusion Antibodies Price Performance

The company has a quick ratio of 2.36, a current ratio of 3.87 and a debt-to-equity ratio of 2.40. The company has a 50 day simple moving average of GBX 7.77 and a 200-day simple moving average of GBX 5.20. The stock has a market cap of £8.11 million, a price-to-earnings ratio of -212.50 and a beta of 0.49.

Fusion Antibodies (LON:FAB) last announced its quarterly earnings data on Tuesday, November 19th. The company reported GBX (0.80) (($0.01)) earnings per share (EPS) for the quarter. Fusion Antibodies had a negative return on equity of 152.68% and a negative net margin of 195.95%. As a group, research analysts anticipate that Fusion Antibodies plc will post -129.9999875 EPS for the current fiscal year.

About Fusion Antibodies

Fusion is a Belfast based contract research organisation (“CRO”) providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.

The Company’s ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation.